Full Text Journal Articles by
Author Olov Wiklund

Advertisement

Find full text journal articles






High prevalence of genetic determined familial hypercholesterolemia in premature coronary artery disease.

Carlo Pirazzi, Lina Håkansson, Carola Gustafsson, Elmir Omerovic, Olov Wiklund, Rosellina Margherita Mancina,

Background: Premature coronary artery disease (CAD) is a major cause of mortality and morbidity. Increased low-density lipoprotein-cholesterol (LDL-C) level is a major risk factor for CAD and thus the main target for its prevention. Familial Hypercholesterolemia (FH) is a genetic inherited disorder characterized by high LDL-C, and subsequent premature CAD ... Read more >>

Appl Clin Genet (The application of clinical genetics)
[2019, 12:71-78]

Cited: 0 times

View full text PDF listing >>



Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract.

François Mach, Kausik K Ray, Olov Wiklund, Alberto Corsini, Alberico L Catapano, Eric Bruckert, Guy De Backer, Robert A Hegele, G Kees Hovingh, Terry A Jacobson, Ronald M Krauss, Ulrich Laufs, Lawrence A Leiter, Winfried März, Børge G Nordestgaard, Frederick J Raal, Michael Roden, Raul D Santos, Evan A Stein, Erik S Stroes, Paul D Thompson, Lale Tokgözoglu, Georgirene D Vladutiu, Baris Gencer, Jane K Stock, Henry N Ginsberg, M John Chapman, ,

To objectively appraise evidence for possible adverse effects of long-term statin therapy on glucose homeostasis, cognitive, renal and hepatic function, and risk for haemorrhagic stroke or cataract.A literature search covering 2000-2017 was performed. The Panel critically appraised the data and agreed by consensus on the categorization of reported adverse effects. ... Read more >>

Eur. Heart J. (European heart journal)
[2018, 39(27):2526-2539]

Cited: 8 times

View full text PDF listing >>



Advertisement

New prospects for PCSK9 inhibition?

Ulf Landmesser, M John Chapman, Jane K Stock, Pierre Amarenco, Jill J F Belch, Jan Borén, Michel Farnier, Brian A Ference, Stephan Gielen, Ian Graham, Diederick E Grobbee, G Kees Hovingh, Thomas F Lüscher, Massimo F Piepoli, Kausik K Ray, Erik S Stroes, Olov Wiklund, Stephan Windecker, Jose Luis Zamorano, Fausto Pinto, Lale Tokgözoglu, Jeroen J Bax, Alberico L Catapano, ,

Eur. Heart J. (European heart journal)
[2018, 39(27):2600-2601]

Cited: 2 times

View full text PDF listing >>



New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk.

Ian Graham, Chuck Shear, Pieter De Graeff, Caroline Boulton, Alberico L Catapano, Wendy Gattis Stough, Stefan C Carlsson, Guy De Backer, Joseph Emmerich, Scott Greenfeder, Albert M Kim, Dominik Lautsch, Tu Nguyen, Steven E Nissen, Krishna Prasad, Kausik K Ray, Jennifer G Robinson, William J Sasiela, Karsten Bruins Slot, Erik Stroes, Tom Thuren, Bart Van der Schueren, Maja Velkovski-Rouyer, Scott M Wasserman, Olov Wiklund, Emmanouil Zouridakis, ,

The very high occurrence of cardiovascular events presents a major public health issue, because treatment remains suboptimal. Lowering LDL cholesterol (LDL-C) with statins or ezetimibe in combination with a statin reduces major adverse cardiovascular events. The cardiovascular risk reduction in relation to the absolute LDL-C reduction is linear for most ... Read more >>

Eur Heart J Cardiovasc Pharmacother (European heart journal. Cardiovascular pharmacotherapy)
[2018, 4(2):119-127]

Cited: 1 time

View full text PDF listing >>



2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.

Ulf Landmesser, M John Chapman, Jane K Stock, Pierre Amarenco, Jill J F Belch, Jan Borén, Michel Farnier, Brian A Ference, Stephan Gielen, Ian Graham, Diederick E Grobbee, G Kees Hovingh, Thomas F Lüscher, Massimo F Piepoli, Kausik K Ray, Erik S Stroes, Olov Wiklund, Stephan Windecker, Jose Luis Zamorano, Fausto Pinto, Lale Tokgözoglu, Jeroen J Bax, Alberico L Catapano,

Eur. Heart J. (European heart journal)
[2018, 39(14):1131-1143]

Cited: 24 times

View full text PDF listing >>



European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk.

Ulf Landmesser, M. John Chapman, Michel Farnier, Baris Gencer, Stephan Gielen, G Kees Hovingh, Thomas F Lüscher, David Sinning, Lale Tokgözoglu, Olov Wiklund, Jose Luis Zamorano, Fausto J Pinto, Alberico L Catapano, , ,

Eur. Heart J. (European heart journal)
[2017, 38(29):2245-2255]

Cited: 40 times

View full text PDF listing >>



[PCSK9 inhibitors reduces LDL cholesterol by 60 percent].

Peter Nilsson, Olov Wiklund,

Lakartidningen (Lakartidningen)
[2017, 114:]

Cited: 0 times

View full text PDF listing >>



2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

Alberico L Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M John Chapman, Heinz Drexel, Arno W Hoes, Catriona S Jennings, Ulf Landmesser, Terje R Pedersen, Željko Reiner, Gabriele Riccardi, Marja-Riita Taskinen, Lale Tokgozoglu, W M Monique Verschuren, Charalambos Vlachopoulos, David A Wood, Jose Luis Zamorano, , Marie-Therese Cooney,

Rev Esp Cardiol (Engl Ed) (Revista espanola de cardiologia (English ed.))
[2017, 70(2):115]

Cited: 4 times

View full text PDF listing >>



2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

Alberico L Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M John Chapman, Heinz Drexel, Arno W Hoes, Catriona S Jennings, Ulf Landmesser, Terje R Pedersen, Željko Reiner, Gabriele Riccardi, Marja-Riita Taskinen, Lale Tokgozoglu, W M Monique Verschuren, Charalambos Vlachopoulos, David A Wood, Jose Luis Zamorano, Marie-Therese Cooney, ,

Eur. Heart J. (European heart journal)
[2016, 37(39):2999-3058]

Cited: 378 times

View full text PDF listing >>



2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).

, Massimo F Piepoli, Arno W Hoes, Stefan Agewall, Christian Albus, Carlos Brotons, Alberico L Catapano, Marie-Therese Cooney, Ugo Corrà, Bernard Cosyns, Christi Deaton, Ian Graham, Michael Stephen Hall, F D Richard Hobbs, Maja-Lisa Løchen, Herbert Löllgen, Pedro Marques-Vidal, Joep Perk, Eva Prescott, Josep Redon, Dimitrios J Richter, Naveed Sattar, Yvo Smulders, Monica Tiberi, H Bart van der Worp, Ineke van Dis, W M Monique Verschuren, , , Guy De Backer, Marco Roffi, Victor Aboyans, Norbert Bachl, Héctor Bueno, Scipione Carerj, Leslie Cho, John Cox, Johan De Sutter, Günther Egidi, Miles Fisher, Donna Fitzsimons, Oscar H Franco, Maxime Guenoun, Catriona Jennings, Borut Jug, Paulus Kirchhof, Kornelia Kotseva, Gregory Y H Lip, François Mach, Giuseppe Mancia, Franz Martin Bermudo, Alessandro Mezzani, Alexander Niessner, Piotr Ponikowski, Bernhard Rauch, Lars Rydén, Adrienne Stauder, Guillaume Turc, Olov Wiklund, Stephan Windecker, Jose Luis Zamorano,

Eur J Prev Cardiol (European journal of preventive cardiology)
[2016, 23(11):NP1-NP96]

Cited: 212 times

View full text PDF listing >>



2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).

, Alberico L Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M John Chapman, Heinz Drexel, Arno W Hoes, Catriona S Jennings, Ulf Landmesser, Terje R Pedersen, Željko Reiner, Gabriele Riccardi, Marja-Riita Taskinen, Lale Tokgozoglu, W M Monique Verschuren, Charalambos Vlachopoulos, David A Wood, Jose Luis Zamorano,

Atherosclerosis (Atherosclerosis)
[2016, 253:281-344]

Cited: 125 times

View full text PDF listing >>



Identification and characterization of two novel mutations in the LPL gene causing type I hyperlipoproteinemia.

Piero Pingitore, Saverio Massimo Lepore, Carlo Pirazzi, Rosellina Margherita Mancina, Benedetta Maria Motta, Luca Valenti, Knut Erik Berge, Kjetil Retterstøl, Trond P Leren, Olov Wiklund, Stefano Romeo,

Type 1 hyperlipoproteinemia is a rare autosomal recessive disorder most often caused by mutations in the lipoprotein lipase (LPL) gene resulting in severe hypertriglyceridemia and pancreatitis.The aim of this study was to identify novel mutations in the LPL gene causing type 1 hyperlipoproteinemia and to understand the molecular mechanisms underlying ... Read more >>

J Clin Lipidol (Journal of clinical lipidology)
[2016, 10(4):816-823]

Cited: 3 times

View full text PDF listing >>



Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine.

Børge G Nordestgaard, Anne Langsted, Samia Mora, Genovefa Kolovou, Hannsjörg Baum, Eric Bruckert, Gerald F Watts, Grazyna Sypniewska, Olov Wiklund, Jan Borén, M John Chapman, Christa Cobbaert, Olivier S Descamps, Arnold von Eckardstein, Pia R Kamstrup, Kari Pulkki, Florian Kronenberg, Alan T Remaley, Nader Rifai, Emilio Ros, Michel Langlois, ,

AIMS:To critically evaluate the clinical implications of the use of non-fasting rather than fasting lipid profiles and to provide guidance for the laboratory reporting of abnormal non-fasting or fasting lipid profiles. METHODS AND RESULTS:Extensive observational data, in which random non-fasting lipid profiles have been compared with those determined under fasting ... Read more >>

Clin. Chem. (Clinical chemistry)
[2016, 62(7):930-946]

Cited: 36 times

View full text PDF listing >>



The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent.

Rosellina Margherita Mancina, Paola Dongiovanni, Salvatore Petta, Piero Pingitore, Marica Meroni, Raffaela Rametta, Jan Borén, Tiziana Montalcini, Arturo Pujia, Olov Wiklund, George Hindy, Rocco Spagnuolo, Benedetta Maria Motta, Rosaria Maria Pipitone, Antonio Craxì, Silvia Fargion, Valerio Nobili, Pirjo Käkelä, Vesa Kärjä, Ville Männistö, Jussi Pihlajamäki, Dermot F Reilly, Jose Castro-Perez, Julia Kozlitina, Luca Valenti, Stefano Romeo,

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver damage and is characterized by steatosis. Genetic factors increase risk for progressive NAFLD. A genome-wide association study showed that the rs641738 C>T variant in the locus that contains the membrane bound O-acyltransferase domain-containing 7 gene (MBOAT7, also called LPIAT1) ... Read more >>

Gastroenterology (Gastroenterology)
[2016, 150(5):1219-1230.e6]

Cited: 75 times

View full text PDF listing >>



Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine.

Børge G Nordestgaard, Anne Langsted, Samia Mora, Genovefa Kolovou, Hannsjörg Baum, Eric Bruckert, Gerald F Watts, Grazyna Sypniewska, Olov Wiklund, Jan Borén, M John Chapman, Christa Cobbaert, Olivier S Descamps, Arnold von Eckardstein, Pia R Kamstrup, Kari Pulkki, Florian Kronenberg, Alan T Remaley, Nader Rifai, Emilio Ros, Michel Langlois, ,

AIMS:To critically evaluate the clinical implications of the use of non-fasting rather than fasting lipid profiles and to provide guidance for the laboratory reporting of abnormal non-fasting or fasting lipid profiles. METHODS AND RESULTS:Extensive observational data, in which random non-fasting lipid profiles have been compared with those determined under fasting ... Read more >>

Eur. Heart J. (European heart journal)
[2016, 37(25):1944-1958]

Cited: 86 times

View full text PDF listing >>



Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER.

Björn W Karlson, Olov Wiklund, Michael K Palmer, Stephen J Nicholls, Pia Lundman, Philip J Barter,

Patient response to statin treatment is individual and varied. As a consequence, when using a specific-dose approach, as recommended in the 2013 American College of Cardiology/American Heart Association guideline, there will be a range of reductions in the concentration of low-density lipoprotein cholesterol (LDL-C). The aim of this study was ... Read more >>

Eur Heart J Cardiovasc Pharmacother (European heart journal. Cardiovascular pharmacotherapy)
[2016, 2(4):212-217]

Cited: 9 times

View full text PDF listing >>



[2016 ESC/EAS Guidelines for the Management of Dyslipidaemias].

Alberico L Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M John Chapman, Heinz Drexel, Arno W Hoes, Catriona S Jennings, Ulf Landmesser, Terje R Pedersen, Željko Reiner, Gabriele Riccardi, Marja-Riita Taskinen, Lale Tokgozoglu, W M Monique Verschuren, Charalambos Vlachopoulos, David A Wood, Jose Luis Zamorano,

Kardiol Pol (Kardiologia polska)
[2016, 74(11):1234-1318]

Cited: 3 times

View full text PDF listing >>



Think Again About Cholesterol Survey.

Alberico L Catapano, Olov Wiklund, ,

Cardiovascular disease (CVD) is still the main cause of death in Europe. Elevated plasma cholesterol, specifically low-density lipoprotein cholesterol (LDL-C), is the main causative risk factor for CVD, most prominently associated with coronary heart disease. A widespread disinformation about cholesterol and CVD is one factor underlying a poor compliance to ... Read more >>

Atheroscler Suppl (Atherosclerosis. Supplements)
[2015, 20:1-5]

Cited: 3 times

View full text PDF listing >>



Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.

Albert Wiegman, Samuel S Gidding, Gerald F Watts, M John Chapman, Henry N Ginsberg, Marina Cuchel, Leiv Ose, Maurizio Averna, Catherine Boileau, Jan Borén, Eric Bruckert, Alberico L Catapano, Joep C Defesche, Olivier S Descamps, Robert A Hegele, G Kees Hovingh, Steve E Humphries, Petri T Kovanen, Jan Albert Kuivenhoven, Luis Masana, Børge G Nordestgaard, Päivi Pajukanta, Klaus G Parhofer, Frederick J Raal, Kausik K Ray, Raul D Santos, Anton F H Stalenhoef, Elisabeth Steinhagen-Thiessen, Erik S Stroes, Marja-Riitta Taskinen, Anne Tybjærg-Hansen, Olov Wiklund, ,

Familial hypercholesterolaemia (FH) is a common genetic cause of premature coronary heart disease (CHD). Globally, one baby is born with FH every minute. If diagnosed and treated early in childhood, individuals with FH can have normal life expectancy. This consensus paper aims to improve awareness of the need for early ... Read more >>

Eur. Heart J. (European heart journal)
[2015, 36(36):2425-2437]

Cited: 123 times

View full text PDF listing >>



Statin use and non-alcoholic steatohepatitis in at risk individuals.

Paola Dongiovanni, Salvatore Petta, Ville Mannisto, Rosellina Margherita Mancina, Rosaria Pipitone, Vesa Karja, Marco Maggioni, Pirjo Kakela, Olov Wiklund, Enrico Mozzi, Stefania Grimaudo, Dorota Kaminska, Raffaela Rametta, Antonio Craxi, Silvia Fargion, Valerio Nobili, Stefano Romeo, Jussi Pihlajamaki, Luca Valenti,

Excess hepatic free cholesterol contributes to the pathogenesis of non-alcoholic steatohepatitis, and statins reduce cholesterol synthesis. Aim of this study was to assess whether statin use is associated with histological liver damage related to steatohepatitis.The relationship between statin use, genetic risk factors, and liver damage was assessed in a multi-center ... Read more >>

J. Hepatol. (Journal of hepatology)
[2015, 63(3):705-712]

Cited: 68 times

View full text PDF listing >>



[Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society].

Marina Cuchel, Eric Bruckert, Henry N Ginsberg, Frederick J Raal, Raul D Santos, Robert A Hegele, Jan Albert Kuivenhoven, Børge G Nordestgaard, Olivier S Descamps, Elisabeth Steinhagen-Thiessen, Anne Tybjaerg-Hansen, Gerald F Watts, Maurizio Averna, Catherine Boileau, Jan Borén, Alberico L Catapano, Joep C Defesche, G Kees Hovingh, Steve E Humphries, Petri T Kovanen, Luis Masana, Päivi Pajukanta, Klaus G Parhofer, Kausik K Ray, Anton F H Stalenhoef, Erik Stroes, Marja-Riitta Taskinen, Albert Wiegman, Olov Wiklund, M John Chapman, ,

Turk Kardiyol Dern Ars (Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir)
[2015, 43 Suppl 1:1-14]

Cited: 0 times

View full text PDF listing >>



Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.

Erik S Stroes, Paul D Thompson, Alberto Corsini, Georgirene D Vladutiu, Frederick J Raal, Kausik K Ray, Michael Roden, Evan Stein, Lale Tokgözoğlu, Børge G Nordestgaard, Eric Bruckert, Guy De Backer, Ronald M Krauss, Ulrich Laufs, Raul D Santos, Robert A Hegele, G Kees Hovingh, Lawrence A Leiter, Francois Mach, Winfried März, Connie B Newman, Olov Wiklund, Terry A Jacobson, Alberico L Catapano, M John Chapman, Henry N Ginsberg, ,

Statin-associated muscle symptoms (SAMS) are one of the principal reasons for statin non-adherence and/or discontinuation, contributing to adverse cardiovascular outcomes. This European Atherosclerosis Society (EAS) Consensus Panel overviews current understanding of the pathophysiology of statin-associated myopathy, and provides guidance for diagnosis and management of SAMS. Statin-associated myopathy, with significant elevation ... Read more >>

Eur. Heart J. (European heart journal)
[2015, 36(17):1012-1022]

Cited: 279 times

View full text PDF listing >>



Comment to the position paper on global recommendations for the management of dyslipidemia developed by the International Atherosclerosis Society (IAS).

Alberico L Catapano, M J Chapman, Guy de Backer, Marja-Riitta Taskinen, Zeljko Reiner, Olov Wiklund,

Atherosclerosis (Atherosclerosis)
[2014, 233(2):508-509]

Cited: 1 time

View full text PDF listing >>



Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group.

Michel R Langlois, Olivier S Descamps, Arnoud van der Laarse, Cas Weykamp, Hannsjörg Baum, Kari Pulkki, Arnold von Eckardstein, Dirk De Bacquer, Jan Borén, Olov Wiklund, Païvi Laitinen, Wytze P Oosterhuis, Christa Cobbaert, ,

BACKGROUND: Despite international standardization programs for LDLc and HDLc measurements, results vary significantly with methods from different manufacturers. We aimed to simulate the impact of analytical error and hypertriglyceridemia on HDLc- and LDLc-based cardiovascular risk classification. METHODS: From the Dutch National EQA-2012 external quality assessment of 200 clinical laboratories, we ... Read more >>

Atherosclerosis (Atherosclerosis)
[2014, 233(1):83-90]

Cited: 10 times

View full text PDF listing >>



[Equal key messages in guidelines for lipids for cardiovascular prevention. European and American recommendations are based on risk stratification].

Olov Wiklund,

Lakartidningen (Lakartidningen)
[2014, 111(14):604-605]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
2.4429 s